Passage Bio Q2 EPS $(0.44) Beats $(0.48) Estimate, Passage Bio Q1 EPS $(0.63) Misses $(0.49) Estimate; Cash, Cash Equivalents And Marketable Securities Of $151.5M Expected To Fund Operations Into Q4 2025
Portfolio Pulse from Benzinga Newsdesk
Passage Bio (NASDAQ:PASG) reported Q2 losses of $(0.44) per share, beating the analyst consensus estimate of $(0.48) by 8.33 percent. This represents a 39.73 percent increase over losses of $(0.73) per share from the same period last year.
August 07, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Passage Bio's Q2 earnings beat analyst estimates, showing a significant improvement from last year's losses.
Passage Bio's Q2 earnings beat analyst estimates, which is generally seen as a positive sign by investors. The significant improvement from last year's losses also indicates that the company's financial situation is improving, which could lead to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100